We retrospectively reviewed acute toxicity with cetuximab and radiotherapy, comparing it
with a matched cisplatin group. The cetuximab group experienced significantly more toxicity …

PURPOSE: To report toxicity data from the first 13 consecutive patients with locally
advanced head and neck squamous cell carcinoma (LAHNSCC), ineligible for cisplatin …

Background Intensification of chemoradiation for advanced head and neck squamous cell
carcinoma (HNSCC) is unlikely due to toxicity. Cetuximab combined either with radiotherapy …

Objectives We previously reported inferior outcomes for locally-advanced head and neck
squamous cell carcinoma (LAHNSCC) patients treated with concurrent cetuximab vs. high …

Background We conducted a multinational, randomized study to compare radiotherapy
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …

Purpose: Treatment with cisplatin or cetuximab combined with radiotherapy each yield
superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) …

Purpose No randomized trials have been conducted to directly compare radiotherapy (RT)
with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

Purpose This study describes the long-term survival and toxicity outcomes of a multicenter
randomized phase 2 trial comparing radiation therapy (RT) plus cisplatin (CDDP) or …

Efficacy of cisplatin versus cetuximab with radiation in locally advanced head and neck
cancer (LAHNC) was evaluated. A total of 96 patients with newly diagnosed LAHNC treated …